北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail
作者: Meng, Xue1; Wang, Jianhua2; Sun, Xindong1; Wang, Lvhua3; Ye, Ming4; Feng, Pingbo5; Zhu, Guangying6; Lu, You7; Han, Chun8; Zhu, Shuchai8; Liao, Zhongxing9; Yu, Jinming1
关键词: Esophagus carcinoma ; Cetuximab ; Chemoradiotherapy ; Phase II
刊名: RADIOTHERAPY AND ONCOLOGY
发表日期: 2013-11-01
DOI: 10.1016/j.radonc.2013.09.008
卷: 109, 期:2, 页:275-280
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Radiology, Nuclear Medicine & Medical Imaging
研究领域[WOS]: Oncology ; Radiology, Nuclear Medicine & Medical Imaging
关键词[WOS]: COLORECTAL-CANCER ; MUTATIONS ; TRIAL
英文摘要:

Background and purpose: This multicenter phase II trial investigated cetuximab combined with chemoradiotherapy in patients with esophageal squamous cell carcinoma (ESCC).

Material and methods: Eligible patients with non-resectable, locally-advanced ESCC received cetuximab 400 mg/m(2) loading dose on day 1; and on day 1 of the 2nd-7th weeks: cetuximab 250 mg/m(2), paclitaxel 45 mg/m(2), and cisplatin 20 mg/m(2), concurrent with 59.4 Gy/33 fractions of radiation therapy. Primary endpoint was clinical response rate. Secondary endpoints included overall survival (OS), progression-free survival (PFS), safety, and KRAS status.

Results: Of 55 patients enrolled, 45 completed therapy. Forty-four patients had a clinical response: 29 complete response and 15 partial response. One-year PFS and OS of 45 evaluable patients were 84.23% and 93.33%, respectively, and 2-year PFS and OS were 74.87% and 80.00%, respectively. Non-hematologic adverse events were generally grade 1 or 2; primarily rash (92.7%), mucositis (45.5%), fatigue (41.8%), and nausea (38.2%). Grade 3 hematologic adverse events included neutropenia (32.7%) and anemia (1.8%). No KRAS mutations were identified in 50 evaluated samples.

Conclusions: Cetuximab can be safely administered with chemoradiotherapy to patients with locally-advanced ESCC and may improve clinical response rate. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

语种: 英语
WOS记录号: WOS:000329019900017
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/54110
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Zhengzhou Univ, Canc Hosp, Zhengzhou, Peoples R China
2.Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China
3.Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
4.Shandong Canc Hosp & Inst, Dept Radiat Oncol, Jinan 250117, Shandong, Peoples R China
5.Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Beijing 100730, Peoples R China
6.Shanghai Jiao Tong Univ, Renji Hosp, Shanghai 200030, Peoples R China
7.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing, Peoples R China
8.Sichuan Univ, West China Sch Med, West China Hosp, Chengdu 610064, Peoples R China
9.Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA

Recommended Citation:
Meng, Xue,Wang, Jianhua,Sun, Xindong,et al. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trail[J]. RADIOTHERAPY AND ONCOLOGY,2013,109(2):275-280.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Meng, Xue]'s Articles
[Wang, Jianhua]'s Articles
[Sun, Xindong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Meng, Xue]‘s Articles
[Wang, Jianhua]‘s Articles
[Sun, Xindong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace